Clinical Trials

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

180 enrolled 14 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07423611 2026-02-20

RACE

388 enrolled

Breast Neoplasms

NCT03624244 2026-02-17

BFR-ESS

40 enrolled

Gynecologic

Endometrial Stromal Tumors

NCT06970912 2026-01-21

DNADalHR

393 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT04762979 2026-01-02

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

44 enrolled

Hormone Receptor Positive Breast Carcinoma

NCT02760030 2025-12-19

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

14 enrolled

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT06361940 2025-10-14

MAPPER

100 enrolled

Breast Neoplasms

NCT04227327 2025-07-29

HERMIONE-7

Phase 2 Terminated

31 enrolled

Advanced Breast Cancer

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Breast Neoplasms

NCT05190094 2025-05-07

ICRG0201

80 enrolled

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03477396 2024-02-20

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

2 enrolled 13 charts

Estrogen Receptor and/or Progesterone Receptor Positive

NCT04240106 2024-02-16

LUZERN

14 enrolled

Breast Neoplasms

NCT05949541 2024-02-08

BCTOP-L-M01

265 enrolled

Breast Neoplasms

NCT05640778 2024-01-31

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

30 enrolled

Luminal B/HER2-negative Breast Cancer

NCT00499083 2023-09-29

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

17 enrolled 5 charts

Breast Neoplasms

NCT03917082 2023-06-15

LALEAST

290 enrolled

Breast Cancer Female

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

150 enrolled

Breast Neoplasms

NCT00828854 2022-06-30

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

27 enrolled 13 charts

Breast Neoplasms

NCT02213042 2021-10-13

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

42 enrolled 13 charts

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT01491737 2020-10-28

PERTAIN

258 enrolled 18 charts

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

10 enrolled

Breast Neoplasms

NCT01446159 2020-06-02

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

188 enrolled 32 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

77 enrolled

Breast Diseases, Breast Neoplasms

NCT02970682 2019-07-12

STEM

60 enrolled

Breast Neoplasms

NCT04012918 2019-07-09

CONCEPT

124 enrolled

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

250 enrolled

Breast Diseases, Breast Neoplasms

NCT02910050 2017-12-22

BETTER

58 enrolled

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT01654185 2017-03-14

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

60 enrolled

Breast Neoplasms

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

226 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01814865 2013-12-20

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Breast Neoplasms

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

100 enrolled

Breast Neoplasms

NCT00080613 2013-07-10

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Breast Neoplasms

NCT01612728 2013-02-12

AIA

Breast Neoplasms, Arthralgia

NCT00935558 2012-05-31

Dendritic Cell Based Therapy for Breast Cancer Patients